Lonza Group AG




Biotechnology & Medical Research

Market Closed - Swiss Exchange 11:30:11 2024-04-19 EDT 5-day change 1st Jan Change
502.8 CHF -1.45% Intraday chart for Lonza Group AG -6.02% +42.15%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix... Our Logo
Lonza Finance Launches EUR1 Billion 12-Year Euro Bond DJ
Switzerland's Lonza Group Prices EUR1 Billion Bond MT
NeuroSense Therapeutics Ltd. Collaborates with Lonza to Identify Exosome-Based Biomarkers, in Order to Advance Neurodegenerative Disease Treatments and Diagnostics CI
Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate MT
Acumen Pharmaceuticals, Inc. Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer?S Disease CI
Health Care Down on Flight From Risk -- Health Care Roundup DJ
Indices: Five Magnificents instead of Seven Our Logo
Global markets live: UBS, AT&T, Tesla, United Airlines, Humana, Wanda... Our Logo
European Midday Briefing : Stocks Gain as Bonds Track Treasuries Lower DJ
Lonza Group Appoints New CEO; Seeks Lifting of Trading Halt MT
Lonza Taps Siegfried Holding's Wolfgang Wienand as Next CEO DJ
Siegfried CEO Steps Down; Finance Chief Named Interim CEO MT
Lonza Group Poaches Siegfried's CEO MT
Lonza Group AG Announces Chief Executive Officer Changes CI
Global markets live: Super Micro Computer, Boeing, Vale, Tesla, Nvidia, Intel, Nasdaq... Our Logo
Transcript : Lonza Group AG - Special Call
Singaporean Shares Rise Tracking Global Gains; Top Glove’s Shares Up 9% as Losses Shrink MT
Lonza Shares Jump on U.S. Manufacturing Facility Buy From Roche DJ
Luxury stocks drag European equities lower ahead of Fed meeting RE
Lonza Group to Acquire Biologics Site in US for $1.2 billion MT
Lonza to Buy U.S. Manufacturing Facility From Roche For $1.2 Billion DJ
Lonza to Buy US Biologics Manufacturing Site from Roche for $1.2 Billion MT
Lonza to buy biologics site from Roche in US for $1.2 bln RE
Lonza to acquire biologics site from Roche in U.S. for $1.2 billion RE
Chart Lonza Group AG
More charts
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (13.2%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%); - other (2.8%). Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
502.8 CHF
Average target price
566 CHF
Spread / Average Target
  1. Stock Market
  2. Equities
  3. LONN Stock
  4. News Lonza Group AG
  5. AlphaValue/Baader Europe Lifts Price Target on Lonza Group, Maintains Add Recommendation